过去一年中添加的文章,按日期排序
Synthetic biology tools to study and overcome drug resistance
J Reynolds - 2024 - etda.libraries.psu.edu
2 天前 - … achieved some success in managing disease progression after the failure of frontline
… for drug resistant disease. Next, we perform a collateral sensitivity screen of a lung cancer …
… for drug resistant disease. Next, we perform a collateral sensitivity screen of a lung cancer …
Metastatic Non-Myofibroblastic Sarcoma Harbouring EML4-ALK Fusion-Dramatic Response to ALK Tyrosine Kinase Inhibitors and Development of Resistance …
I Wilson, M Qiu, M Itchins, B Wang… - Cancer reports …, 2024 - pubmed.ncbi.nlm.nih.gov
2 天前 - … After progression on first line systemic therapy with doxorubicin, the patient received
… sensitivity in non-lung ALK rearranged tumours, contrary to experience in lung cancer. …
… sensitivity in non-lung ALK rearranged tumours, contrary to experience in lung cancer. …
Immunotherapy and PD-L1 Tumor Expression in Moroccan Non-Small Cell Lung Cancer Patients with Various Metastasis
O Aazzane, S Fathi, M Charkaoui… - … Journal of Cancer …, 2024 - journal.waocp.org
3 天前 - … The aim of this study is to evaluate the predictive significance of tumor expression
of PD-L1 as well as the number and site of metastasis in non-small cell lung cancer (NSCLC) …
of PD-L1 as well as the number and site of metastasis in non-small cell lung cancer (NSCLC) …
Immunotherapy shapes B-cell receptor repertoire to induce anti-tumor antibodies production in colon and lung cancer
H Su, Y Wang, S Khan, Y Huang, Z Yi, N Zhu… - … Instability & Disease, 2024 - Springer
3 天前 - Immunotherapy has made remarkable progress within the past decade, but the role
of B cells in tumor immunity remains unclear. Here, we show that the combination therapy of …
of B cells in tumor immunity remains unclear. Here, we show that the combination therapy of …
Mutation of MET D1228N as an Acquired Potential Mechanism of Crizotinib Resistance in NSCLC with MET Y1003H Mutation
J Zhu, J Chen, W Liu, J Zhang, Y Gu - Lung Cancer: Targets and …, 2024 - Taylor & Francis
3 天前 - … In addition, during disease progression, we first identified MET D1228N as a potential
mechanism for crizotinib resistance in this patient. This finding provides new insights into …
mechanism for crizotinib resistance in this patient. This finding provides new insights into …
A review of advances in analytical strategies for RNA methylation
H Sun, F Yin, Z Zou, Y Gu, C Guo - Analytica Chimica Acta, 2024 - Elsevier
3 天前 - … , which plays critical roles in the bouts and progression of diseases such as breast
cancer, gastric carcinoma, lung cancer, and brain tumor. Molecular mechanisms and clinical …
cancer, gastric carcinoma, lung cancer, and brain tumor. Molecular mechanisms and clinical …
… of the effect of baseline detection and early clearance of ct-DNA, on survival outcomes among patients with advanced EGFR-mutant non-small cell lung cancer
3 天前 - … lung cancer (NSCLC) with inferior survival outcomes, we analyzed and compared
survival outcomes among patients with and without baseline presence and early clearance of …
survival outcomes among patients with and without baseline presence and early clearance of …
[HTML][HTML] Appropriate delay of primary tumour radiotherapy may lead to better long-term overall survival for non-small cell lung cancer treated with EGFR-TKIs
Q Li, N Liang, W Ouyang, S Su, Z Ma, Y Geng, Y Hu… - BMC cancer, 2024 - Springer
3 天前 - … with oligoprogressive disease in EGFR-mutated non-small cell lung cancer [18,
31, 32]. Our study suggested that primary tumor radiotherapy after disease progression(R PD ) …
31, 32]. Our study suggested that primary tumor radiotherapy after disease progression(R PD ) …
Real world outcomes of patients with radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) treated in 1l with lenvatinib 24 mg: an international multicenter …
L Locati, T Gordoa, L Lamartina, M Luster… - Endocrine …, 2024 - endocrine-abstracts.org
4 天前 - Objectives: Lenvatinib was approved for the treatment of patients with radioiodine-refractory
differentiated thyroid cancer (RAI-R DTC) in Europe in 2015 and Canada in 2016. …
differentiated thyroid cancer (RAI-R DTC) in Europe in 2015 and Canada in 2016. …
Clinicopathological characteristics and outcome of patients with poorly differentiated thyroid cancer-a single center experience
V Antonopoulou, T Stratigou, M Zotou… - Endocrine …, 2024 - endocrine-abstracts.org
4 天前 - … 6/23 (4 females) were diagnosed with PDTC during progression of papillary DTC.
Clinicopathological characteristics are reported in the following table. Patients with de novo …
Clinicopathological characteristics are reported in the following table. Patients with de novo …